UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

Nature communications, 2022-02, Vol.13 (1), p.896-19, Article 896

2022

Volltextzugriff (PDF)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-03, Vol.17 (3), p.367-377

2016

Volltextzugriff (PDF)

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

Clinical cancer research, 2008-03, Vol.14 (5), p.1368-1376

2008

Volltextzugriff (PDF)

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Clinical cancer research, 2012-04, Vol.18 (8), p.2402-2412

2012

Volltextzugriff (PDF)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors

BMC cancer, 2018-07, Vol.18 (1), p.732-732, Article 732

2018

Volltextzugriff (PDF)

TIM-3 expression in breast cancer

Oncoimmunology, 2018-11, Vol.7 (11), p.e1502128-e1502128

2018

Volltextzugriff (PDF)

Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada

Current oncology (Toronto), 2023-08, Vol.30 (8), p.7263-7274

2023

Volltextzugriff (PDF)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.692-700

2009

Volltextzugriff (PDF)

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

Breast cancer research and treatment, 2016-02, Vol.155 (3), p.483-490

2016

Volltextzugriff (PDF)

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2716-2725

2005

Volltextzugriff (PDF)

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.153-162

2014

Volltextzugriff (PDF)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Breast cancer research : BCR, 2017-05, Vol.19 (1), p.54-8, Article 54

2017

Volltextzugriff (PDF)

IGF-1R inhibition: right direction, wrong pathway?

The lancet oncology, 2013-03, Vol.14 (3), p.182-183

2013

Volltextzugriff (PDF)

Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Journal of clinical oncology, 2023-08, Vol.41 (24), p.JCO2300759-3983

2023

Volltextzugriff (PDF)

Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival

Journal of clinical oncology, 2006-12, Vol.24 (36), p.5637-5644

2006

Volltextzugriff (PDF)

Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3660-3668

2001

Volltextzugriff (PDF)

Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease

American Society of Clinical Oncology educational book, 2015 (35), p.e41-e48

Chia, Stephen K

2015

Volltextzugriff (PDF)

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Clinical cancer research, 2020-10, Vol.26 (19), p.5172-5177

2020

Volltextzugriff (PDF)

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response

Journal of clinical oncology, 2024-07, Vol.42 (20), p.2372-2376

2024

Volltextzugriff (PDF)

Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies

Journal of clinical oncology, 2004-05, Vol.22 (9), p.1630-1637

2004

Volltextzugriff (PDF)

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 + -Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC)

Clinical cancer research, 2017-07, Vol.23 (14), p.3529-3536

2017

Volltextzugriff (PDF)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

JNCI : Journal of the National Cancer Institute, 2009-05, Vol.101 (10), p.736-750

2009

Volltextzugriff (PDF)

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.88-99

2019

Volltextzugriff (PDF)

Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (15), p.5068-5073

2004

Volltextzugriff (PDF)

1 – 25 von 290

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(257)

Publikationsform

Sprache

Englisch
(288)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors

TIM-3 expression in breast cancer

Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

IGF-1R inhibition: right direction, wrong pathway?

Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival

Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma

Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response

Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 + -Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression

Suchergebnisse filtern